By Eric Langer, Kamna Jhamb, and Ronald Rader
We follow up our Parts 1 and 2 discussion of the impact of Covid-19 on bioprocessing, based on our recent White Paper that is also included in our research, (see www.bioplanassociates.com/17th). We interviewed major biopharmaceutical industry senior bioprocessing decision-makers, and bioprocessing suppliers in the US and Europe. The long-term effects on the biopharma and bioprocessing industry will likely impact emerging (smaller) biopharma companies and suppliers in similar ways. For example, greater outsourcing will likely increase the number and size of projects for the larger Contract Manufacturing Organizations’. But it will also create opportunities for smaller, and niche CMOs.